icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
AMaRC 16-01 - RECRUITMENT CLOSED

STUDY TITLE

A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone (MRd) in Relapsed Refractory Multiple Myeloma

 

STUDY DESIGN

Multicentre, open label, sequential cohort study

 

CORRELATIVE STUDIES

Blood and bone marrow samples are collected for biomarkers to correlate clinical response, patterns of clonal evolution during therapy and assessment of minimal residual disease (MRd) resistance

 

TRIAL PRINCIPAL INVESTIGATOR

Professor Andrew Spencer and Associate Professor Jake Shortt

 

TIME FRAME

2016 – 2019

 

PARTICIPANTS

60 patients with relapsed refractory multiple myeloma (RR MM) who have received 1-3 prior lines of therapy

 

CURRENT ENROLMENT

Stage 1: 19

Stage 2: 40 

 

STATUS

Stage 1: Closed to recruitment

Stage 2: Closed to recruitment

 

SITE LOCATIONS